Insider Trading Alert - CHRW, IPXL And ALOG Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Friday, May 23, 2014, 112 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $90.00 to $7,463,228.50.

Highlighted Stocks Traded by Insiders:

CH Robinson Worldwide (CHRW) - FREE Research Report

Campbell Ben G, who is VP-General Counsel & Secretary at CH Robinson Worldwide, sold 100 shares at $59.11 on May 23, 2014. Following this transaction, the VP-General Counsel & Secretary owned 38,814 shares meaning that the stake was reduced by 0.26% with the 100-share transaction.

The shares most recently traded at $59.46, up $0.35, or 0.59% since the insider transaction. Historical insider transactions for CH Robinson Worldwide go as follows:

  • 4-Week # shares bought: 400
  • 4-Week # shares sold: 100
  • 12-Week # shares bought: 400
  • 12-Week # shares sold: 100
  • 24-Week # shares bought: 400
  • 24-Week # shares sold: 100

The average volume for CH Robinson Worldwide has been 1.8 million shares per day over the past 30 days. CH Robinson Worldwide has a market cap of $8.9 billion and is part of the services sector and transportation industry. Shares are up 2.19% year-to-date as of the close of trading on Friday.

C.H. Robinson Worldwide, Inc., a third party logistics company, provides freight transportation services and logistics solutions to companies in various industries worldwide. The stock currently has a dividend yield of 2.35%. The company has a P/E ratio of 22.6. Currently, there are 2 analysts who rate CH Robinson Worldwide a buy, 5 analysts rate it a sell, and 9 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CHRW - FREE

TheStreet Quant Ratings rates CH Robinson Worldwide as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, notable return on equity and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full CH Robinson Worldwide Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Impax Laboratories (IPXL) - FREE Research Report

Hsu Larry, who is Director at Impax Laboratories, sold 50,000 shares at $27.22 on May 23, 2014. Following this transaction, the Director owned 409,568 shares meaning that the stake was reduced by 10.88% with the 50,000-share transaction.

The shares most recently traded at $28.01, up $0.79, or 2.83% since the insider transaction. Historical insider transactions for Impax Laboratories go as follows:

  • 4-Week # shares sold: 282,701
  • 12-Week # shares sold: 286,701
  • 24-Week # shares sold: 289,701

The average volume for Impax Laboratories has been 771,600 shares per day over the past 30 days. Impax Laboratories has a market cap of $2.0 billion and is part of the health care sector and drugs industry. Shares are up 10.94% year-to-date as of the close of trading on Friday.

Impax Laboratories, Inc., a specialty pharmaceutical company, develops, manufactures, and markets bioequivalent pharmaceutical products; and develops and markets branded products. The company operates through two segments, Global Pharmaceuticals Division and Impax Pharmaceutical Division. The company has a P/E ratio of 2723.0. Currently, there are 2 analysts who rate Impax Laboratories a buy, 2 analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on IPXL - FREE

TheStreet Quant Ratings rates Impax Laboratories as a hold. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, expanding profit margins and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and weak operating cash flow. Get the full Impax Laboratories Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Analogic (ALOG) - FREE Research Report

Fry John J, who is Sr. VP / Gen. Counsel /Sec. at Analogic, sold 425 shares at $76.13 on May 23, 2014. Following this transaction, the Sr. VP / Gen. Counsel /Sec. owned 15,796 shares meaning that the stake was reduced by 2.62% with the 425-share transaction.

The shares most recently traded at $68.21, down $7.92, or 11.61% since the insider transaction. Historical insider transactions for Analogic go as follows:

  • 4-Week # shares sold: 3,108
  • 12-Week # shares sold: 10,459
  • 24-Week # shares sold: 14,733

The average volume for Analogic has been 119,800 shares per day over the past 30 days. Analogic has a market cap of $954.9 million and is part of the health care sector and health services industry. Shares are down 13.14% year-to-date as of the close of trading on Friday.

Analogic Corporation, a technology company, designs, manufactures, and sells medical imaging and security systems and subsystems to original equipment manufacturers and end users in the healthcare and airport security markets worldwide. The stock currently has a dividend yield of 0.52%. The company has a P/E ratio of 29.8. Currently, there are 2 analysts who rate Analogic a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on ALOG - FREE

TheStreet Quant Ratings rates Analogic as a buy. The company's strengths can be seen in multiple areas, such as its increase in net income, revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins and good cash flow from operations. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full Analogic Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

Global Stocks Slide as Trump's New Trade War Salvo Ignites Fresh Concern

Global Stocks Slide as Trump's New Trade War Salvo Ignites Fresh Concern

Trump Tariff Threat, Deutsche Bank, Elon Musk and Apple - 5 Things You Must Know

Trump Tariff Threat, Deutsche Bank, Elon Musk and Apple - 5 Things You Must Know

Automakers Slump as Trump Launches National Security Probe into US Car Imports

Automakers Slump as Trump Launches National Security Probe into US Car Imports

Deutsche Bank Confirms Massive Job Cuts as New CEO Christian Sewing Plants Flag

Deutsche Bank Confirms Massive Job Cuts as New CEO Christian Sewing Plants Flag

Carnival CEO Arnold Donald: China Will Become the Largest Cruise Market

Carnival CEO Arnold Donald: China Will Become the Largest Cruise Market